natgillin/translations-raw huggingface dataset:
Of 131 patients who responded to ustekinumab induction, and were randomized to the placebo group at the start of the maintenance study, 51 subsequently lost response and received 90 mg ustekinumab subcutaneously every 8 weeks. 
Med 131 bolniki, ki so se odzvali na indukcijo z ustekinumabom in so bili na začetki vzdrževalne študije randomizirani v skupino, ki je prejemala placebo, jih je 51 izgubilo odziv na zdravljenje in so prešli na subkutano odmerjanje 90 mg ustekinumaba na 8 tednov.
In developmental and reproductive toxicity studies in cynomolgus monkeys, neither adverse effects on male fertility indices nor birth defects or developmental toxicity were observed. 
V študijah toksičnosti za razvoj in sposobnost razmnoževanja pri opicah Cynomolgus niso opazili niti neželenih učinkov na pokazatelje plodnosti pri samcih, niti prirojenih anomalij ali toksičnosti za razvoj pri mladičih.
Paediatric patients 6 years and older with plaque psoriasis The safety of ustekinumab has been studied in two phase 3 studies of paediatric patients with moderate to severe plaque psoriasis. 
Pediatrični bolniki s psoriazo s plaki, stari 6 let in več Varnost ustekinumaba so preučevali v dveh študijah faze 3 pri pediatričnih bolnikih z zmerno do hudo psoriazo s plaki.
In Psoriasis Study 2, the Hospital Anxiety and Depression Scale (HADS) and Work Limitations Questionnaire (WLQ) were also significantly improved in each ustekinumab treatment group compared with placebo. 
V 2. študiji psoriaze sta bila tudi rezultata Bolnišnične lestvice tesnobe in depresije (Hospital Anxiety and Depression Scale - HADS) in vprašalnika o delovnih omejitvah (WLQ - Work Limitations Questionnaire) v obeh terapevtskih skupinah z ustekinumabom bistveno izboljšana v primerjavi s placebom.
In a population pharmacokinetic analysis, the apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.465 l/day and 15.7 l, respectively, in patients with psoriasis. 
V analizi populacijske farmakokinetike pri bolnikih s psoriazo je znašal navidezni očistek zdravila (CL/F) 0,465 l/dan, navidezni porazdelitveni volumen (V/F) pa 15,7 l. Spol ni vplival na CL/F ustekinumaba.
Do not use Stelara: 
Ne uporabljajte zdravila Stelara
• the pre-filled syringe is not damaged 
• da napolnjena injekcijska brizga ni poškodovana,
Single doses up to 6 mg/kg have been administered intravenously in clinical studies without dose-limiting toxicity. 
V kliničnih študijah so bolnikom dajali enkratne intravenske odmerke do 6 mg/kg, brez toksičnih učinkov, ki bi omejevali odmerek zdravila.
• If someone will assist in giving you the injection, then he or she may also choose the upper arms as an injection site. 
• Če vam bo kdo drug dal injekcijo, lahko za mesto injiciranja izbere tudi nadlaket.
Ustekinumab cannot bind to IL-12 or IL-23 that is already bound to IL-12R1 cell surface receptors. 
Ustekinumab se ne more vezati na interlevkina IL-12 in IL-23, ki sta že vezana na receptorje IL-12R1 na celični površini.
Remove the needle cover (see Figure 3): 
Odstranite pokrovček z igle (glejte Sliko 3)
In clinical studies, patients with latent tuberculosis who were concurrently treated with isoniazid did not develop tuberculosis. 
Pri bolnikih z latentno tuberkulozo, ki so bili sočasno zdravljeni z izoniazidom, se v kliničnih študijah ni pojavila tuberkuloza.
All patients were followed for up to 52 weeks following first administration of study treatment. 
Vse bolnike so spremljali do 52 tednov po prvem prejemu proučevanega zdravila.
Patients who were re-randomised to placebo at week 40 reinitiated ustekinumab at their original dosing regimen when they experienced at least a 50% loss of their PASI improvement obtained at week 40. 
Bolnikom, ki so jih kasneje naključno uvrstili v skupino za prejemanje placeba v 40. tednu, so potem ponovno uvedli ustekinumab v prvotni shemi odmerjanja, če so pri njih opazili najmanj 50% upad izboljšanja indeksa PASI, doseženega v 40. tednu.
The most serious adverse reaction that has been reported for STELARA is serious hypersensitivity reactions including anaphylaxis (see section 4.4). 
Najresnejši neželeni učinek, o katerem so poročali pri uporabi zdravila STELARA, je huda preobčutljivostna reakcija, vključno z anafilakso (glejte poglavje 4.4).
Table 7 Summary of primary and secondary endpoints at week 12 and week 52 Paediatric psoriasis study (CADMUS) (Age 12-17) Week 12 
Preglednica 7: Povzetek primarnih in sekundarnih ciljev v 12. in 52. tednu Študija pediatrične psoriaze (CADMUS) (12-17 let) 12. teden
In a population pharmacokinetic analysis using data from patients with psoriasis, body weight was found to be the most significant covariate affecting the clearance of ustekinumab. 
V analizi populacijske farmakokinetike, kjer so uporabili podatke bolnikov s psoriazo, so ugotovili, da je med drugimi spremenljivkami, ki vplivajo na očistek ustekinumaba, najpomembnejša telesna masa.
In rare cases, allergic lung reactions and lung inflammation have been reported in patients who receive ustekinumab. 
V redkih primerih so pri bolnikih, ki so prejemali ustekinumab, poročali o alergijskih reakcijah pljuč in vnetju pljuč.
Crohn's disease or Ulcerative Colitis 
Crohnova bolezen ali ulcerozni kolitis
Women of childbearing potential should use effective methods of contraception during treatment and for at least 15 weeks after treatment. 
Ženske v rodni dobi morajo med zdravljenjem in do 15 tednov po njem uporabljati učinkovito in varno kontracepcijsko metodo.
Patients in UNITI-2 had failed at least one conventional therapy, including corticosteroids or immunomodulators, and were either anti-TNF-α naïve (68.6%) or had previously received but not failed anti-TNFα therapy (31.4%). 
Pri bolnikih v študiji UNITI-2 je bilo neuspešno najmanj eno konvencionalno zdravljenje (vključno s kortikosteroidi ali imunomodulatorji) in se še niso zdravili z zaviralci TNFα (68,6%) ali pa so se zdravili z zaviralci TNFα in se na zdravljenje niso odzvali (31,4%).
Approximately 50% of the patients had failed at least 1 prior anti-TNF therapy (of which 48% were primary non-responders) and 17% had failed at least 1 anti-TNFα therapy and vedolizumab. 
Pri približno 50% bolnikov je bilo neuspešno najmanj eno predhodno zdravljenje z zaviralcem TNF (med njimi je bilo 48% bolnikov primarno neodzivnih na zdravljenje), pri 17% pa je bilo neuspešno zdravljenje z najmanj enim zaviralcem TNFα in vedolizumabom.
No studies have been conducted that include patients with a history of malignancy or that continue treatment in patients who develop malignancy while receiving STELARA. 
Študij še niso izvedli pri bolnikih, ki so imeli v pretekli anamnezi malignom, ter pri tistih, ki so zdravljenje z zdravilom STELARA nadaljevali tudi po pojavu malignoma.
No new safety concerns were identified in this study extension with up to 2 years of treatment in patients with Crohn's Disease. 
V tej podaljšani študiji s trajanjem zdravljenja do 2 leti pri bolnikih s Crohnovo boleznijo niso ugotovili nobenih novih tveganj glede varnosti.
• Infections of the nose or throat and common cold are common (may affect up to 1 in 
• Pogoste so okužbe nosu ali žrela in prehlad (pojavijo se lahko pri več kot 1 od
Driving and using machines Stelara has no or negligible influence on the ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Stelara nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
STELARA, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1). 
Zdravilo STELARA je kot samostojno zdravilo ali v kombinaciji z MTX indicirano za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih, če je bil odziv na predhodno zdravljenje z nebiološkimi protirevmatičnimi zdravili (DMARD- Disease-Modifying Antirheumatic Drugs) nezadosten (glejte poglavje 5.1).
The most common adverse reactions (> 5%) in controlled periods of the adult psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis clinical studies with ustekinumab were nasopharyngitis and headache. 
Najpogostejša neželena učinka (> 5%) v nadzorovanih obdobjih kliničnih študij psoriaze, psoriatičnega artritisa, Crohnove bolezni in ulceroznega kolitisa z ustekinumabom pri odraslih sta bila nazofaringitis in glavobol.
The absolute bioavailability of ustekinumab following a single subcutaneous administration was estimated to be 57.2% in patients with psoriasis. 
Po enkratni subkutani injekciji je bila absolutna biološka uporabnost ustekinumaba pri bolnikih s psoriazo ocenjena na 57,2%.
• After the starting dose, you will have the next dose 4 weeks later, and then every 12 weeks. 
• Po začetnem odmerku boste po 4 tednih prejeli naslednji odmerek, nadaljne odmerke pa boste prejemali na vsakih 12 tednov.
In clinical studies, serious bacterial, fungal, and viral infections have been observed in patients receiving STELARA (see section 4.8). 
V kliničnih študijah so pri bolnikih, ki so prejemali zdravilo STELARA, opazili resne bakterijske, glivične in virusne okužbe (glejte poglavje 4.8).
Improvements in PGA, PASI, and CDLQI were maintained through week 52 (Table 8). 
Izboljšanje v PGA, PASI in CDLQI se je ohranilo do 52. tedna (Preglednica 8).
In the placebo-controlled studies of patients with psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, the rates of infection or serious infection were similar between ustekinumab-treated patients and those treated with placebo. 
V s placebom nadzorovanih študijah pri bolnikih s psoriazo, psoriatičnim artritisom, Crohnovo boleznijo in ulceroznim kolitisom so bile pogostnosti okužb in resnih okužb pri bolnikih, zdravljenih z ustekinumabom, podobne kot pri tistih, ki so prejemali placebo.
• During treatment, the first dose of approximately 6 mg/kg Stelara will be given by your doctor through a drip in a vein in your arm (intravenous infusion). 
• Med zdravljenjem vam bo dal prvi odmerek zdravila Stelara, približno 6 mg/kg, vaš zdravnik v obliki kapljične infuzije v eno od ven na roki (intravenska infuzija).
Latex sensitivity 
Preobčutljivost za lateks
Secondary endpoints included PASI 75, PASI 90, and change from baseline in Children's Dermatology Life Quality Index (CDLQI) at week 12. 
Sekundarni cilji so vključevali PASI 75, PASI 90 in spremembo od izhodiščne vrednosti dermatološkega indeksa kakovosti življenja pri otrocih (CDLQI - Children's Dermatology Life Quality Index) v 12. tednu.
• Hold the syringe with the needle pointing up to see if it has any air bubbles inside 
• Brizgo držite tako, da bo igla gledala navzgor, in preverite, ali je v brizgi kakšen mehurček.
53% of these patients were either non-responsive, intolerant, or had a contraindication to other systemic therapy. 
53% teh bolnikov se bodisi ni odzvalo na drugo sistemsko zdravljenje, ga niso prenašali ali pa so imeli kontraindikacije zanj.
• Push the needle through the rubber stopper 
• Iglo potisnite skozi gumijasti zamašek.
The median steady-state trough concentration ranged from 0.21 μg/mL to 0.26 μg/mL (45 mg) and from 0.47 μg/mL to 0.49 μg/mL (90 mg). 
Mediana vrednost najmanjše koncentracije v stanju dinamičnega ravnovesja se je gibala od 0,21 μg/ml do 0,26 μg/ml (45 mg) in od 0,47 μg/ml do 0,49 μg/ml (90 mg).
The beneficial effect of ustekinumab on clinical response, mucosal healing and clinical remission was observed in induction and in maintenance both in patients who failed conventional therapy but not a biologic therapy, as well as in those who had failed at least one prior TNFα antagonist therapy including in patients with a primary non-response to TNFα antagonist therapy. 
Ugoden učinek ustekinumaba na klinični odziv, zacelitev sluznice in klinično remisijo so opazili pri indukcijskem in vzdrževalnem zdravljenju tako pri bolnikih z neuspešnim konvencionalnim zdravljenjem, ne pa neuspešnim zdravljenjem z biološkim zdravilom, kot tudi pri tistih z neuspešnim predhodnim zdravljenjem z najmanj enim od zaviralcev TNFα, kar vključuje bolnike, ki so primarno neodzivni na zdravljenje z zaviralci TNFα.
PASI 75 responders PASI 90 responders PASI 100 responders CDLQI 
Odziv PASI 75 Odziv PASI 90 Odziv PASI 100 CDLQI CDLQI 0 ali 1
Caution should be exercised when considering the use of STELARA in patients with a chronic infection or a history of recurrent infection (see section 4.3). 
Ko razmišljate o uporabi zdravila STELARA pri bolnikih s kronično okužbo ali ponavljajočimi se okužbami v anamnezi, je potrebna previdnost (glejte poglavje 4.3).
• Serious allergic reactions (‘anaphylaxis') are rare in people taking Stelara (may affect up to 1 in 1,000 people). 
• Hude alergijske reakcije (‘anafilaksija') so pri bolnikih, ki jemljejo zdravilo Stelara, redke (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
• It is preferable to avoid the use of Stelara in pregnancy. 
• Uporaba zdravila Stelara ni priporočljiva med nosečnostjo.
Health-related quality of life was assessed by Inflammatory Bowel Disease Questionnaire (IBDQ) and SF-36 questionnaires. 
Z zdravjem povezano kakovost življenja so ocenjevali z vprašalniki za oceno vnetnih bolezni črevesja (IBDQ - Inflammatory Bowel Disease Questionnaire) in SF-36 (Short Form-36).
The safety and efficacy of ustekinumab was assessed in 1,996 patients in two randomised, double-blind, placebo-controlled studies in patients with moderate to severe plaque psoriasis and who were candidates for phototherapy or systemic therapy. 
Varnost in učinkovitost ustekinumaba so ocenili pri 1.996 bolnikih v dveh randomiziranih, dvojno slepih in s placebom nadzorovanih študijah pri bolnikih z zmerno do hudo psoriazo s plaki, ki so bili kandidati za fototerapijo ali sistemsko terapijo.
The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn's disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn's disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in patients with ulcerative colitis. 
Sočasna uporaba MTX, NSAID, 6-merkaptopurina, azatioprina in peroralnih kortikosteroidov pri bolnikih s psoriatičnim artritisom, Crohnovo boleznijo ali ulceroznim kolitisom ali predhodna izpostavljenost zaviralcem TNFα pri bolnikih s psoriatičnim artritisom ali Crohnovo boleznijo ali predhodna izpostavljenost biološkim zdravilom (zaviralcem TNFα in/ali vedolizumabu) pri bolnikih z ulceroznim kolitisom ni vplivala na farmakokinetiko ustekinumaba.
Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. 
Ustekinumab je popolnoma človeško monoklonsko protitelo IgG1κ, ki se specifično veže na p40, skupno proteinsko podenoto človeških citokinov interlevkinov (IL)-12 in IL-23.
• Common signs of an allergic reaction include skin rash and hives (these may affect up to 1 in 100 people). 
• Pogosti znaki alergijske reakcije vključujejo kožni izpuščaj in koprivnico (pojavijo se lahko pri največ 1 od 100 bolnikov).
A higher proportion of patients treated with ustekinumab who had spondylitis with peripheral arthritis as their primary presentation, demonstrated 50 and 70 percent improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores compared with placebo at week 24. 
Večjemu deležu bolnikov s spondilitisom s perifernim artritisom je zdravljenje z ustekinumabom izboljšalo oceno po Bathovem indeksu aktivnosti ankilozirajočega spondilitisa (BASDAI-Bath Ankylosing Spondylitis Disease Activity Index) za 50% in 70% v primerjavi s placebom po 24 tednih.
p < 0.001 for ustekinumab 45 mg or 90 mg in comparison with placebo (PBO). 
p < 0,001 za odmerek 45 mg ali 90 mg ustekinumaba v primerjavi s placebom (PBO).
If infection has been excluded and diagnosis is confirmed, discontinue ustekinumab and institute appropriate treatment (see section 4.8). 
Ob prisotnosti okužbe in potrjeni diagnozi, je treba zdravljenje z ustekinumabom prekiniti in uvesti primerno zdravljenje (glejte poglavje 4.8).
PGA of cleared (0) or minimal 
PGA čisto (0) ali minimalno
Any unused product remaining in the syringe should be thrown away. 
Neuporabljeno zdravilo, ki ostane v brizgi je treba zavreči.
The median time to reach the maximum serum concentration (tmax) was 8.5 days after a single 90 mg subcutaneous administration in healthy subjects. 
Pri zdravih preizkušancih je bila mediana vrednost časa do doseganja največje serumske koncentracije (tmax) po enkratni 90 mg subkutani injekciji zdravila 8,5 dni.
A combined endpoint of histo-endoscopic mucosal healing defined as subjects having both mucosal healing and histologic healing was evaluated at week 8 of UNIFI-I and week 44 of UNIFI-M. 
Kombiniran cilj opazovanja histološko endoskopske zacelitve sluznice, ki je bil definiran kot bolniki, pri katerih je prišlo tako do zacelitve sluznice kot histološke zacelitve, so ocenjevali v 8. tednu študije UNIFI-I in v 44. tednu študije UNIFI-M.
In these studies, 2.2% of 785 placebo treated patients and 1.9% of 790 patients treated with the recommended dose of ustekinumab reported adverse events occurring during or within an hour of the infusion. 
V teh študijah je o neželenih učinkih med infuzijo ali v eni uri po infuziji poročalo 2,2% od 785 bolnikov, zdravljenih s placebom in 1,9% od 790 bolnikov, zdravljenih s priporočenim odmerkom ustekinumaba.
At 1 year (week 52), 89% of patients re-randomised to maintenance treatment were PASI 75 responders compared with 63% of patients re-randomised to placebo (treatment withdrawal) (p < 0.001). 
Po enem letu (52. teden) je 89% bolnikov, ki so bili ponovno naključno uvrščeni v skupino za vzdrževalno zdravljenje, pokazalo odziv PASI 75, v primerjavi s 63% bolnikov, ki so bili ponovno naključno uvrščeni v skupino za prejemanje placeba (prenehanje zdravljenja) (p < 0,001).
If you do not respond well enough or are intolerant to these medicines, you may be given Stelara to reduce the signs and symptoms of your disease. 
Če odziv na zdravljenje s temi zdravili ni bil zadosten ali jih niste prenašali, lahko zdravnik za zmanjšanje znakov in simptomov bolezni uvede zdravljenje z zdravilom Stelara.
Do not touch the plunger while you do this 
Pri tem se ne dotikajte bata.
Dispose of your sharps container according to your local regulations 
Te posode odstranite skladno z lokalnimi predpisi.
• When the plunger is pushed as far as it will go, take out the needle and let go of the skin 
• Ko ste bat potisnili do konca, vzemite iglo ven in spustite kožo.
In this study, 29.1% of the patients had an inadequate initial response (primary non-responders), 69.4% responded but lost response (secondary non-responders), and 36.4% were intolerant to antiTNFα therapies. 
Pri 29,1% bolnikov v tej študiji je bil začetni odziv na zdravljenje z zaviralci TNFα nezadosten (primarno neodzivni bolniki), 69,4% bolnikov se je sprva odzvalo, a so odziv izgubili (sekundarno neodzivni bolniki), 36,4% bolnikov pa zdravljenja ni prenašalo.
Serum ustekinumab concentrations in paediatric psoriasis patients 6 to 17 years of age, treated with the recommended weight-based dose were generally comparable to those in the adult psoriasis population treated with the adult dose. 
Serumske koncentracije ustekinumaba pri pediatričnih bolnikih s psoriazo, starih 6 do 17 let, zdravljenih s priporočenim odmerkom glede na telesno maso so bile v splošnem primerljive s tistimi pri odrasli populaciji bolnikov s psoriazo, ki so prejemali priporočeni odmerek za odrasle.
Crohn's Disease and Ulcerative Colitis 
Crohnova bolezen in ulcerozni kolitis
At week 12, subjects treated with ustekinumab showed clinically meaningful improvements in their psoriasis and health related quality of life (Table 8). 
V 12. tednu so pri preiskovancih, zdravljenih z ustekinumabom ugotovili klinično pomembnejše izboljšanje psoriaze in izboljšanje z zdravjem povezane kakovosti življenja (Preglednica 8).
• Psoriatic arthritis - in adults 
• psoriatični artritis pri odraslih
In Crohn's disease and ulcerative colitis studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of STELARA. 
V študijah Crohnove bolezni in ulceroznega kolitisa sočasna uporaba imunosupresivov ali kortikosteroidov ni vplivala na varnost ali učinkovitost zdravila STELARA.
No adverse effects on female fertility indices were observed using an analogous antibody to IL-12/23 in mice. 
Pri miših niso opazili nobenih neželenih učinkov na pokazatelje plodnosti pri samicah pri uporabi analognega protitelesa IL-12/23.
Withdraw and then discard a volume of the sodium chloride 9 mg/mL (0.9%) solution from the 250 mL infusion bag equal to the volume of STELARA to be added (discard 26 mL sodium chloride for each vial of STELARA needed, for 2 vials- discard 52 mL, for 3 vials discard 78 mL, for 4 vials- discard 104 mL). 
Iz 250 ml infuzijske vrečke odvzemite volumen 9 mg/ml (0,9%) raztopine natrijevega klorida, ki ustreza volumnu zdravila STELARA, ki ga boste dodali (za eno vialo zdravila STELARA odvzemite in zavrzite 26 ml natrijevega klorida, za dve viali 52 ml, za 3 viale 78 ml, za 4 viale 104 ml).
61% of these patients were either non-responsive, intolerant, or had a contraindication to other systemic therapy. 
61% teh bolnikov se bodisi ni odzvalo na drugo sistemsko zdravljenje, ga niso prenašali ali pa so imeli kontraindikacije zanj.
The proportion of patients achieving a clinically significant improvement in fatigue (4 points in FACIT-F) was also significantly greater in the ustekinumab groups compared with placebo. 
Tudi delež bolnikov, ki so dosegli klinično pomembno izboljšanje utrujenosti (4 točke po FACIT-F), je bil pomembno večji v skupini z ustekinumabom.
STELARA is available in a 1 vial pack or a pack of 1 pre-filled syringe. 
Zdravilo STELARA je na voljo v pakiranjih z 1 vialo ali v pakiranjih z 1 napolnjeno injekcijsko brizgo.
Table 9: Induction of Clinical Response and Remission in UNITI-1 and UNITI 2 UNITI-1* 
Preglednica 9: Indukcija kliničnega odziva in klinične remisije v študijah UNITI-1 in UNITI-2 UNITI-1*
Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin (IL)-12/23 produced in a murine myeloma cell line using recombinant DNA technology. 
Ustekinumab je popolnoma človeško monoklonsko protitelo IgG1κ proti interlevkinu (IL)-12/23, izdelano v celični liniji mišjega plazmocitoma s tehnologijo rekombinantne DNA.
Table 3: Induction of Clinical Response and Remission in UNITI-1 and UNITI 2 UNITI-1* 
Preglednica 3: Indukcija kliničnega odziva in klinične remisije v študijah UNITI-1 in UNITI-2 UNITI-1*
These improvements were maintained in ustekinumab-treated patients in UNIFI-M through week 44. 
Ta izboljšanja so se pri bolnikih, zdravljenih z ustekinumabom v študiji UNIF-M, ohranila do 44. tedna.
The needle cover on the syringe in the STELARA pre-filled syringe is manufactured from dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex. 
Pokrovček za iglo napolnjene injekcijske brizge vsebuje naravno gumo (lateks), ki lahko povzroči alergijske reakcije pri posameznikih s preobčutljivostjo na lateks.
Stelara contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'. 
Zdravilo STELARA vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
49% of patients had failed conventional therapy, but not a biologic (of which 94% where biological-naïve). 
Pri 49% bolnikov je bilo neuspešno predhodno konvencionalno zdravljenje, ne pa zdravljenje z biološkim zdravilom (med temi bolniki jih 94% predhodno ni prejemalo biološkega zdravila).
• The needle cover should not be removed until you are ready to inject the dose 
• Pokrovčka ne snemajte z igle, dokler niste pripravljeni za injiciranje odmerka.
* Following response to IV ustekinumab. 
* po odzivu na intravenski odmerek ustekinumaba.